Who are we?
Tzamal has been at the forefront of medical technology representing some of the most distinguished medical device companies in the world, for more than 35 years. During its first 25 years, the company represented established companies and focused on direct sales. Companies which chose Tzamal to represent them include Johnson & Johnson, Ohmeda (B&D) and Schneider (Pfizer).
Medical Innovation Specialists
Just over a decade ago Tzamal embarked on a bold and new path and therefore underwent a major reorganization. The company decided to devote almost a third of its resources to representing up and coming med-techs offering unique, innovative solutions. An intensive marketing program was introduced, specifically designed to familiarize the medical community with medical innovations. Thanks to this strategy, Tzamal is today recognized for its expertise in promoting and achieving sales for young medical technology innovators. The company is proud of its unique ability to break-down barriers and guide hospital administrators throughout replacement of obsolete medical technologies with innovative ones.
Putting Patients First
Stunning results have shown the new company succeeded in surpassing the sales peak of its predecessor within half the time. Today Tzamal enjoys annual sales of over $27 million and growing. The secret of our success lies in great part in our continuous pursue for better patient care as a main goal..Our commitment to state-of-the art health care is what drives our outstanding results.
Tzamal is active in most major med-tech markets via its six subsidiaries:
Tzamal Jakobsohn – Innovative devices and technology for surgery, orthopedics, cardiology, neurosurgery and spinal applications.
Tzamal Bio-Pharma – Specialty biotechnologies and pharmaceuticals, orphan drugs for rare diseases
Tzamal M.P.VET – Veterinary products, technologies and equipment
Tzamal 2B Capital Medical Equipment – High-tech capital equipment for all areas of healthcare industry
Tzamal Medicare – Innovative technology for primary and home care
Tzamal D-Chem Laboratories – Chemicals for research
Actively Advancing Innovation
Besides marketing existing products\companies, Tzamal is also greatly involved in development of innovative new medical technologies by mentoring and financing promising medical technology start-ups in a wide variety of fields. Via its subsidiary Tzamal Investments the company is closely guiding and financing some two dozen young companies.
Drugs Disributed by Tzamal Bio-Pharma Ltd
Antiplatelet Agent. Tirofiban HCl Monohydrate 0.05 mg/ml. VIAL FOR INJECT: 1 x 12.5 mg/50 ml
INFUS. BAG: 1 x 12.5 mg/250 ml (0.05
mg/ml). Initial: 0.4 μg/kg/min of
diluted sol. by I.V. Then 0.1 μg/kg/min.
In comb. with heparin in unstable
ang. or non-Q-wave M.I., prevent card.
ischem. events, acute coronary syndr.
(incl. medically managed and
undergoing PTCA or atherectomy). See
Angiotensin II Antagonist, Diuretics. Candesartan Cilexetil 16 mg, Hydrochlorothiazide 12.5 mg. TABS: 28. 1 tab x dly with or without
food. Elderly: No special dosage. Use
in pts with impair. ren. fusal: see lit.
Not recommend. for child.
Antihypertens. effect usually attained
within 4 wks.
Essent. hypertens. where monother. with
candesartan cilexetil or HCTZ is not
C/I: Hypersens., severe ren. impair.,
severe hepat. impair and / or cholestas.,
Nitrogen mustard analogues. Bendamustine Hydrochloride 25,100 mg. VIAL(Pwdr. for concentrate for sol. for IV infus.):1×25,100 mg.
Monother. for CLL 100 mg/m² bdy. surface area bendamustine HCl on days 1 and 2; every 4 wks. up to 6 times.
Monother. for indolent non-Hodgkin’s lymphomas refract. to rituximab
120 mg/m² bdy. surface area bendamustine HCl on days 1 and 2;
every 3 wks. for at least 6 times.
Follicular non-Hodgkin’s lymphoma: Comb. with rituximab
The dose is 90 mg/m² body surface area bendamustine HCl on days 1 and 2
plus 375 mg/m² rituximab on day 1; repetition every 4 wks. See lit.
1st -line of CLL (Binet stage B or C) in pts. for whom fludarabine comb. chemother. is not appropiate. Indolent non-Hodgkin’s lymphomas as monother.in pts., who have progress. during or within 6 mnths. follow. tmt. with rituximab or a rituximab contain. regimen. Follicular non-Hodgkin’s lymphoma as 1st line tmt. in comb. with rituximab.
Sev. hep. impair. (serum bilirub. > 3.0 mg/dl).
Severe bone marrow suppres. and severe blood count alterations (leukocyte and/or platelet values dropped to < 3,000/μl or < 75,000/μl, respectively).
Biphosphonate. Alendronic Acid 70 mg. EFFERVESCENT TABS: 4,12,24. 1 tab (70 mg)×1/week. Missed dose, should be taken one effervescent tab. on the morning after as pt. remembers and return to taking 1 tab (70 mg)×1/week , as original. scheduled on their chosen day.
The tabs. must be taken at least 30 min. before the first food, beverage, or med. product of the day with plain water only. The drug should only be taken upon arising for the day dissolv. in half a glass of plain water (not less than 120 ml or 4.2 fl.oz.). Pts. should not lie down until after their 1st food of the day, which should be at least 30 min. after drinking the oral sol. Pts. should not lie down for at least 30 min. after taking, should not be taken at bedtime or before arising for the day, can be given to pts. who are unable or unwell. to swallow tabs. See lit.
Tmt. of osteoporosis in postmenopaus. women to prevent fractures, include. those of the hip and spine (vertebral compres. fractures).
Tmt. to incr. bone mass in men with osteoporosis.
C/I: Hypersens. Abnormalities of the oesophagus and other factors which delay oesophageal emptying such as stricture or achalasia, Inability to stand or sit upright for at least 30 minutes. Hypocalcaemia.
Antiarrhythmics Class I and III. Vernakalant (as HCl) 20 mg/ml. VIAL: 1×10, 25 ml. Recom. init. infus. is 3 mg/kg to be infus. over a 10 min. period. pts. weigh. ≥ 113 kg, do not exceed the max. init. dose of 339 mg (84.7 ml of 4 mg/ml sol.). If conver. to sinus rhythm does not occur within 15 min. after the end of the init. infus., a 2nd 10 min. infus. of 2 mg/kg may be admin. Pts. weigh. ≥ 113 kg, do not exceed the max. 2nd infus. of 226 mg (56.5 ml of 4 mg/ml sol.). Cumulative doses of greater than 5 mg/kg should not be admin. within 24 hrs. There are no clin. data on repeat doses after the
init. and 2nd infus. By 24 hrs. there
appears to be insignificant levels of
vernakalant. See lit.
Rapid conver. of recent onset atrial fibril.
to sinus rhythm in adults who are
hemodynamic. stable For non-surgery pts.: atrial fibril. ≤ 7 d. duration. For post-cardiac surgery pts.: atrial fibrill.≤ 3 d. duration.
C/I: Hypersen. Pts. with severe aortic
stenosis, pts. with systolic blood pressure
<100 mm Hg, and pts. with Heart fail. class
NYHA III and NYHA IV. Pts. with prolon. QT
at baseline (uncorrected > 440 msec), or
severe bradycar. sinus node dysfunc. or
2nd degree and 3rd degree heart block in
the absence of a pacemaker. Use of IV
rhythm control anti-arrhythmics (class I
and class III) within 4 hrs. prior to, as well
as in the first 4 hrs. after, drug admin.
Acute coron. synd. (includ. MI) within the
last 30 days.